Pasithea Therapeutics Corp.

Yield per half year: -48.32%
Dividend yield: 0%
Sector: Healthcare

Pasithea Therapeutics Corp.

Underestimation

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
P/E
0/10
-0.0556 -268.1 -99.98% -3.29 -98.31%
P/S 21.83 55.96 -60.99%
P/BV 0.2336 251.23 -99.91%
P/FCF -5.6E-5 -196.64 -100%
Ev/Ebitda 0.2618 12.23 -97.86%
Ev/S -7.13 457.86 -101.56%
Ev/FCF 0.000249 -232.19 -100%
E/P -17.99 0.0224 -80540.58%

Efficiency

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Ebitda margin
0/10
-2724.35 -341.3 698.23% -9594.53 -71.61%
ROE -0.1878 103.63 -100.18%
ROA -65.93 -2.84 2222.97%
ROIC 0 1.17 -100%
ROS -2857.74 -298.77 856.51%
ROCE -94.06 -0.0718 130903.54%

Debt

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Debt/Ebitda
10/10
-0.0062 0.9431 -100.65% -0.0226 -72.76%
Nеt Debt/Ebitda 0.5223 1.03 -49.06%
Debt/Ratio 0.0051 0.1785 -97.15%
Debt/Equity 0.0867 1.56 -94.42%
Debt/Net Income -0.0059 -1.48 -99.6%

Dividends

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Dividend yield
0/10
0 0.5195 -100% 0 0%
Number of years of dividend growth 0 0.8444 -100%
DSI 0 0.2147 -100%
Average dividend growth 0 1.27 -100%
Average percentage for 5 years 0 0.5087 -100%
Average percentage for payments 0 59.63 -100%
Difference from average difference in sector -0.5195

Growth impulse

Parameter Grade Value Sector average Difference with sector, %
Growth impulse Revenue in 5 years
10/10
3143.73 -87.95 -3674.45%
Growth impulse Ebitda in 5 years 32230.62 -156.19 -20735.52%
Growth impulse Net Income in 5 years 33813.62 -172.49 -19703.23%
Growth impulse FCF in 5 years 35701023.08 -114.74 -31114814.21%
Growth impulse EPS in 5 years 21220.53 -98.04 -21744.77%
IP Score
4.99/10

Similar companies

Alexion

Gilead Sciences

ABIOMED

Amgen

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription